methyl 2-[[(6-ethyl-2-oxo-1H-quinolin-3-yl)methyl-(2-hydroxyethyl)carbamothioyl]amino]benzoate

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: methyl 2-[[(6-ethyl-2-oxo-1H-quinolin-3-yl)methyl-(2-hydroxyethyl)carbamothioyl]amino]benzoate
• 化学式: C₂₃H₂₅N₃O₄S
• 分子量: 439.5
• InChiKey: HZDIMQJXHLIPKQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  31
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  123
• 氢给体数：
  3
• 氢受体数：
  5

文献信息

• SELECTIVE BETA-GLUCURONIDASE INHIBITORS AS A TREATMENT FOR SIDE EFFECTS OF CAMPTOTHECIN ANTINEOPLASTIC AGENTS
  申请人：Redinbo Matthew R.

  公开号：US20120322797A1

  公开（公告）日：2012-12-20

  Compounds, compositions and methods are provided that comprise selective β-glucuronidase inhibitors for both aerobic and anaerobic bacteria, especially enteric bacteria normally associated with the gastrointestinal tract. The compounds, compositions and methods can be for inhibiting bacterial β-glucuronidases and for improving efficacy of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds by attenuating the side effects caused by reactivation by bacterial β-glucuronidases of glucuronidated metabolites of camptothecin-derived antineoplastic agents or glucuronidase-substrate agents or compounds.
• Methods of Treating Adverse Intestinal Effects of Non-Steroidal Anti-Inflammatory Drugs
  申请人：University of Connecticut

  公开号：US20150011542A1

  公开（公告）日：2015-01-08

  Methods of treating adverse intestinal effects of a non-steroidal anti-inflammatory drugs (NSAID) in a subject by administering to the subject a therapeutically effective amount of a selective bacterial beta-glucuronidase inhibitor. The adverse intestinal effects to be treated include the formation or growth of an intestinal ulcer, increased intestinal permeability, the loss of intestinal villi, bleeding of the intestinal mucosa, and an increased intestinal inflammatory response. The methods are useful for treating the adverse effects of any NSAID such as propionic acid derivatives, carboxylic acid derivatives, enolic acid derivatives, fenamic acid derivatives, sulphonanilidies, and selective COX-2 inhibitors. The bacterial beta-glucuronidase inhibitors are selective for the inhibition of bacterial beta-glucuronidase enzymes and do not inhibit mammalian beta-glucuronidase.
• US8557808B2
  申请人：——

  公开号：US8557808B2

  公开（公告）日：2013-10-15
• US9334288B2
  申请人：——

  公开号：US9334288B2

  公开（公告）日：2016-05-10
• [EN] METHODS OF TREATING ADVERSE INTESTINAL EFFECTS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS<br/>[FR] PROCÉDÉS DE TRAITEMENT D'EFFETS INTESTINAUX DÉFAVORABLES DE MÉDICAMENTS ANTI-INFLAMMATOIRES NON STÉROÏDIENS
  申请人：UNIV CONNECTICUT

  公开号：WO2013106656A2

  公开（公告）日：2013-07-18